Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N Engl J Med. 2016.
PMID: 26981941
No abstract available.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 49 |
| 2017 | 70 |
| 2018 | 58 |
| 2019 | 37 |
| 2020 | 54 |
| 2021 | 45 |
| 2022 | 36 |
| 2023 | 33 |
| 2024 | 24 |
Search Results
373 results
Results by year
Citations
7
articles
found by citation matching
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N Engl J Med. 2016.
PMID: 26981940
No abstract available.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N Engl J Med. 2015.
PMID: 26378978
Clinical Trial.
Search results
Page 1
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
N Engl J Med. 2015.
PMID: 26378978
Free article.
Clinical Trial.
BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not …
BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiov …
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
N Engl J Med. 2020.
PMID: 32865377
Free article.
Clinical Trial.
The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. ...The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. ...
The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. ...The effect of …
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Ann Intern Med. 2020 Aug 18;173(4):278-286. doi: 10.7326/M20-0864. Epub 2020 Jun 30.
Ann Intern Med. 2020.
PMID: 32598218
BACKGROUND: Several pharmacologic options for type 2 diabetes are available. PURPOSE: To compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes. ...In patients at low cardiovascular risk receiving metfo …
BACKGROUND: Several pharmacologic options for type 2 diabetes are available. PURPOSE: To compare benefits and harms of …
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13.
Circulation. 2018.
PMID: 28904068
Clinical Trial.
BACKGROUND: Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and established cardiovascular disease in the EMPA-REG OUTCOM …
BACKGROUND: Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality i …
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28.
Circulation. 2016.
PMID: 27470878
Review.
In contrast, blood pressure lowering, estimated glomerular filtration rate, and albuminuric effects are preserved, and perhaps exaggerated in chronic kidney disease. With regard to long-term clinical outcomes, the EMPA-REG OUTCOME trial (Empagliflozin, Car …
In contrast, blood pressure lowering, estimated glomerular filtration rate, and albuminuric effects are preserved, and perhaps exaggerated i …
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.
Am Heart J. 2022 Nov;253:86-98. doi: 10.1016/j.ahj.2022.05.010. Epub 2022 May 17.
Am Heart J. 2022.
PMID: 35595091
Free article.
Clinical Trial.
BACKGROUND: Patients with acute myocardial infarction (MI) are at risk for developing heart failure (HF) and subsequently are at an increased risk of mortality. Sodium-glucose cotransporter-2 inhibitors have been proven to improve outcomes in patients with HF with r …
BACKGROUND: Patients with acute myocardial infarction (MI) are at risk for developing heart failure (HF) and subsequently are at an increase …
Empagliflozin after Acute Myocardial Infarction.
N Engl J Med. 2024 Apr 25;390(16):1455-1466. doi: 10.1056/NEJMoa2314051. Epub 2024 Apr 6.
N Engl J Med. 2024.
PMID: 38587237
Clinical Trial.
BACKGROUND: Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and efficacy of e …
BACKGROUND: Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type …
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778.
Circulation. 2019.
PMID: 30586757
Free PMC article.
Clinical Trial.
BACKGROUND: In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with type 2 diabetes mellitus and atheroscl …
BACKGROUND: In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Typ …
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.
Lancet. 2020.
PMID: 32877652
METHODS: We did a prespecified meta-analysis of the two single large-scale trials assessing the effects of SGLT2 inhibitors on cardiovascular outcomes in patients with HFrEF with or without diabetes: DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing …
METHODS: We did a prespecified meta-analysis of the two single large-scale trials assessing the effects of SGLT2 inhibitors on cardiovasc …
EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors.
Clin Kidney J. 2023 Jun 16;16(8):1187-1198. doi: 10.1093/ckj/sfad082. eCollection 2023 Aug.
Clin Kidney J. 2023.
PMID: 37529652
Free PMC article.
Around 15% (almost 1000) of participants were not on renin-angiotensin system blockade. The clinical characteristics of the cohort differed from DAPA-CKD (A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in …
Around 15% (almost 1000) of participants were not on renin-angiotensin system blockade. The clinical characteristics of the cohort di …
Cite